Literature DB >> 20305705

Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant.

Peter Bacchetti1, Ross D Boylan, Norah A Terrault, Alexander Monto, Marina Berenguer.   

Abstract

Multistate modeling methods are well-suited for analysis of some chronic diseases that move through distinct stages. The memoryless or Markov assumptions typically made, however, may be suspect for some diseases, such as hepatitis C, where there is interest in whether prognosis depends on history. This paper describes methods for multistate modeling where transition risk can depend on any property of past progression history, including time spent in the current stage and the time taken to reach the current stage. Analysis of 901 measurements of fibrosis in 401 patients following liver transplantation found decreasing risk of progression as time in the current stage increased, even when controlled for several fixed covariates. Longer time to reach the current stage did not appear associated with lower progression risk. Analysis of simulation scenarios based on the transplant study showed that greater misclassification of fibrosis produced more technical difficulties in fitting the models and poorer estimation of covariate effects than did less misclassification or error-free fibrosis measurement. The higher risk of progression when less time has been spent in the current stage could be due to varying disease activity over time, with recent progression indicating an "active" period and consequent higher risk of further progression.

Entities:  

Keywords:  fibrosis; hepatitis C; liver transplant; memoryless assumptions; multistate modeling

Mesh:

Year:  2010        PMID: 20305705      PMCID: PMC2836212          DOI: 10.2202/1557-4679.1213

Source DB:  PubMed          Journal:  Int J Biostat        ISSN: 1557-4679            Impact factor:   0.968


  12 in total

1.  Hidden Markov models for the onset and progression of bronchiolitis obliterans syndrome in lung transplant recipients.

Authors:  Christopher H Jackson; Linda D Sharples
Journal:  Stat Med       Date:  2002-01-15       Impact factor: 2.373

2.  A semiparametric transition model with latent traits for longitudinal multistate data.

Authors:  Haiqun Lin; Zhenchao Guo; Peter N Peduzzi; Thomas M Gill; Heather G Allore
Journal:  Biometrics       Date:  2008-03-19       Impact factor: 2.571

Review 3.  Classification of chronic hepatitis: diagnosis, grading and staging.

Authors:  V J Desmet; M Gerber; J H Hoofnagle; M Manns; P J Scheuer
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

4.  HCV-related fibrosis progression following liver transplantation: increase in recent years.

Authors:  M Berenguer; L Ferrell; J Watson; M Prieto; M Kim; M Rayón; J Córdoba; A Herola; N Ascher; J Mir; J Berenguer; T L Wright
Journal:  J Hepatol       Date:  2000-04       Impact factor: 25.083

5.  Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model.

Authors:  S Deuffic-Burban; T Poynard; A-J Valleron
Journal:  J Viral Hepat       Date:  2002-03       Impact factor: 3.728

6.  Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

Authors:  T Poynard; P Bedossa; P Opolon
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

Review 7.  Diagnosis and quantitation of fibrosis.

Authors:  Diarmuid S Manning; Nezam H Afdhal
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

8.  Exceeding the limits of liver histology markers.

Authors:  Shruti H Mehta; Bryan Lau; Nezam H Afdhal; David L Thomas
Journal:  J Hepatol       Date:  2008-10-18       Impact factor: 25.083

9.  Estimating complex multi-state misclassification rates for biopsy-measured liver fibrosis in patients with hepatitis C.

Authors:  Peter Bacchetti; Ross Boylan
Journal:  Int J Biostat       Date:  2009       Impact factor: 0.968

10.  Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression.

Authors:  Peter Bacchetti; Phyllis C Tien; Eric C Seaberg; Thomas R O'Brien; Michael H Augenbraun; Alex H Kral; Michael P Busch; Brian R Edlin
Journal:  BMC Infect Dis       Date:  2007-12-10       Impact factor: 3.090

View more
  3 in total

1.  Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis.

Authors:  Peter Bacchetti; Ross Boylan; Jacquie Astemborski; Hui Shen; Shruti H Mehta; David L Thomas; Norah A Terrault; Alexander Monto
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

Review 2.  Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management.

Authors:  Bobby Kakati; Anil Seetharam
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

Review 3.  Recurrence of hepatitis C after liver transplantation.

Authors:  Carmen Vinaixa; Angel Rubín; Victoria Aguilera; Marina Berenguer
Journal:  Ann Gastroenterol       Date:  2013
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.